期刊
EXPERT OPINION ON DRUG DELIVERY
卷 17, 期 9, 页码 1189-1211出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2020.1781088
关键词
Intracellular antibody delivery; endosomal escape; polymeric carriers; lipid-based platforms; cell-penetrating peptides
资金
- Australian Research Council Industrial Transformation Training Centres (ARC ITTC) under the ARC Training Centre for Biopharmaceutical Innovation (CBI) [IC160100027]
Introduction Monoclonal antibodies have been utilized in clinical and basic research for the treatment of various malignancies. Whilst all therapeutically approved monoclonal antibodies or fragments thereof are directed against cell-surface receptors or proteins of the human secretome, intracellular antigen targeting strategies still await translation into the clinic. This contradicts the notion of antibodies being the magic bullet concept as many cancer targets are out of reach. Areas covered This review provides a summary of intracellular translocation strategies that were successfully employed for antibody delivery in preclinical studies. Examples encompass a variety of different approaches such as polymeric and lipid-based nanoparticles (NP), biomimetics, bispecific antibody constructs, the use of cell-penetrating peptides, as well as various sophisticated combinations thereof. We will further discuss endosomal escape as the major bottleneck in functional intracellular transport and provide suggestions on how to overcome current challenges. Expert opinion Despite significant advances in protein delivery technologies, reports of highly efficient transport vehicles are sparse when systemically appliedin vivo. Consequently, more detailed mechanistic studies are needed to identify and optimize the molecular 'Achilles heel' of individual methodologies. Ultimately, to target intracellular proteins that have been undruggable in the past, a combination of strategies may be required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据